Article
Medicine, General & Internal
Lijuan Zhang, Xuefei Leng, Fei Tian, Dunming Xiao, Jianwei Xuan, Hongxiu Yang, Jing Liu, Zhihong Chen
Summary: In Qingdao, China, continuous subcutaneous insulin infusion (CSII) therapy has been found to be more cost-effective than multiple daily injections (MDI) therapy for children and adolescent patients with type 1 diabetes (T1D). It should be considered as the preferred treatment modality.
POSTGRADUATE MEDICINE
(2022)
Article
Endocrinology & Metabolism
Mark Warren, Bruce Bode, Jang I. Cho, Rong Liu, Janet Tobian, Thomas Hardy, Farai Chigutsa, Moshe Phillip, Barry Horowitz, Debra Ignaut
Summary: The study found that in patients with type 1 diabetes using CSII, URLi was more effective in improving postprandial glucose control and reducing time spent in hypoglycemia compared to lispro.
DIABETES OBESITY & METABOLISM
(2021)
Article
Public, Environmental & Occupational Health
Keyu Guo, Jiaqi Li, Liyin Zhang, Jianan Ye, Li Fan, Zhiyi Ding, Qin Zhou, Xia Li, Lin Yang, Zhiguang Zhou
Summary: This study compared the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy in Chinese patients with type 1 diabetes mellitus (T1DM). The results showed that CSII therapy was associated with lower HbA1c levels and better glycemic outcomes. However, it did not improve the risk of hypoglycemia.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Xu Wang, Xue Zhao, Danrong Chen, Mingzhi Zhang, Wei Gu
Summary: A comparison of treatment regimens for T1D in children using a combination of meta-analysis and prospective cohort study revealed that CSII may be associated with better glycemic control and growth development without increasing the risk of long-term complications or delaying puberty.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Cesare C. Berra, Maria Chiara Rossi, Marco Mirani, Daniela Ceccarelli Ceccarelli, Cristina Romano, Lorenza Sassi, Elena Peretti, Giuseppe Favacchio, Ida Pastore, Laura Folini, Giusi Graziano, Maria Elena Lunati, Sebastiano Bruno Solerte, Paolo Fiorina
Summary: The aim of this study was to evaluate the real-world impact of once-weekly subcutaneous semaglutide on various aspects of metabolic control, cardiovascular risk factors, and beta-cell function in patients with type 2 diabetes. The results showed that after 6 months of treatment, semaglutide led to significant improvements in HbA1c levels, fasting blood glucose, body weight, blood pressure, and lipid profile. The study also demonstrated the renal safety of semaglutide and its potential role in preserving beta-cell function and modifying insulin resistance.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Lisa A. Amato, Romana Kalolo, William Yu, David Simmons
Summary: This study reports on five patients with type 1 diabetes who underwent continuous subcutaneous insulin infusion therapy. After 2-4 months of treatment, the mean HbA1c level decreased from 9.7% to 7.9%. The frequency of hospital admissions for acute glycaemic events decreased in three patients but increased in two within 6 months. Some patients experienced a decrease in insulin dose and body mass index, and anecdotal evidence suggested increased satisfaction. Not all "frequent flyers" benefited from CSII.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Endocrinology & Metabolism
Jesus Moreno-Fernandez, Ana Chico, Maria Asuncion Martinez-Brocca, Pilar Isabel Beato-Vibora, Merce Vidal, Maria Piedra, Carmen Quiros, Jose Ramon Munoz-Rodriguez
Summary: This study analyzed the clinical effect of continuous subcutaneous insulin infusion (CSII) in the Spanish real-world scenario for patients with type 1 diabetes mellitus (T1D). The findings showed that CSII treatment was associated with a sustained improvement in glycemic control, especially among patients with higher CGM adherence.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Public, Environmental & Occupational Health
Qiong Luo, Li Zhou, Naitong Zhou, Ming Hu
Summary: This study evaluated the long-term cost effectiveness of insulin degludec/insulin aspart (IDegAsp) vs. biphasic insulin aspart 30 (BIAsp 30) for the treatment of Chinese patients with inadequately managed type 2 diabetes mellitus (T2DM). The results showed that IDegAsp was associated with higher life years and quality-adjusted life years compared to BIAsp 30 over a 30-year time horizon. Additionally, the total costs were slightly higher with IDegAsp therapy. Therefore, IDegAsp was considered a cost-effective treatment option for people with inadequate glycemic management on basal insulin in China.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Shun-hua Wang, Wei Shao, Qiu-hui Jiang, Xuan-ling Zheng, Qing-bao Shen, Xiao-yan Lin, Qiao-qing Zhang, Lu-lu Zhang, Xiu-lin Shi, Wen-gui Wang, Xue-jun Li
Summary: This study aimed to explore the risk factors associated with glycemic control in hospitalized patients with type 2 diabetes mellitus (T2DM) treated with Continuous Subcutaneous Insulin Infusion (CSII). Results showed that older age, male gender, lower BMI, lower C-P, higher LDL-C, previous insulin prescriptions, longer duration of diabetes, nephropathy, and retinopathy were risk factors for a higher proportion of hyperglycemic events in these patients. Additionally, lower BMI, lower C-P, lower LDL-C, longer duration of diabetes, and previous insulin prescriptions were important factors for a higher proportion of hypoglycemic events.
Article
Endocrinology & Metabolism
Alexis M. McKee, Noor Al-Hammadi, Leslie J. Hinyard
Summary: A study on young adults with type 1 diabetes found lower utilization of CSII in Black, Hispanic, male, and government-insured individuals, who also had higher HbA1c levels. Black, Hispanic, and government-insured subjects had higher odds of DKA.
ENDOCRINE PRACTICE
(2021)
Review
Chemistry, Medicinal
Hui Li, Aimin Yang, Shi Zhao, Elaine Yk Chow, Mohammad Javanbakht, Yinhui Li, Dandan Lin, Lijuan Xu, Deng Zang, Kai Wang, Li Ma
Summary: The clinical efficacy of continuous subcutaneous insulin infusion (CSII) therapy combined with six classes of oral glucose-lowering drugs (GLDs) in the treatment of type 2 diabetes was evaluated using a network meta-analysis. The results showed that CSII combined with metformin had the best clinical effect in controlling blood sugar and improving insulin resistance.
Article
Endocrinology & Metabolism
Jennifer Leohr, Mary Anne Dellva, Elizabeth Labell, David E. Coutant, Jorge Arrubla, Leona Plum-Moerschel, Eric Zijlstra, Tsuyoshi Fukuda, Thomas Hardy
Summary: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection.
DIABETES OBESITY & METABOLISM
(2023)
Article
Nutrition & Dietetics
Kirthi Menon, Barbora de Courten, Dianna J. Magliano, Zanfina Ademi, Danny Liew, Ella Zomer
Summary: This study assessed the cost-effectiveness of daily 1g carnosine supplementation in addition to standard care for the management of type 2 diabetes and compared it to standard care alone. The results showed that supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia.
Article
Endocrinology & Metabolism
Peipei Shi, Aiqi Hou, Chenchen Li, Xiaodan Wu, Shaowei Jia, Haipeng Cen, Xiaorong Hu, He Gong
Summary: Continuous subcutaneous insulin infusion (CSII) potentially improves bone microstructure, mechanical properties, and metabolic markers in T2DM rats; 8-week CSII treatment is more beneficial for enhancing bone structures and mechanical properties in T2DM rats.
Review
Medicine, General & Internal
Vasiliki Chatziravdeli, George I. I. Lambrou, Athanasia Samartzi, Nikolaos Kotsalas, Eugenia Vlachou, John Komninos, Athanasios N. N. Tsartsalis
Summary: Diabetes mellitus (DM) is becoming more prevalent worldwide, even in developing countries. While there are many antidiabetic agents available, insulin is often necessary for patients with inadequate glycemic control. However, the optimal timing for insulin administration is still a topic of research. This meta-analysis examined the use of continuous subcutaneous insulin infusion (CSII) in patients with Type 2 Diabetes Mellitus (T2DM) and found that CSII may be beneficial in helping patients achieve their glycemic targets.
MEDICINA-LITHUANIA
(2023)